PTCT insider trading
NasdaqGS HealthcarePTC THERAPEUTICS, INC. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About PTC THERAPEUTICS, INC.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
Company website: www.ptcbio.com
PTCT insider activity at a glance
FilingIQ has scored 1,327 insider transactions for PTCT since Jan 13, 2015. The most recent filing in our index is dated May 8, 2026.
Across the full history, 4 open-market purchases
and 766 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on PTCT insider trades is 59.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest PTCT Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding PTCT
Frequently asked
- How many insider trades does FilingIQ track for PTCT?
- FilingIQ tracks 1,327 Form 4 insider transactions for PTCT (PTC THERAPEUTICS, INC.), covering filings from Jan 13, 2015 onwards. 48 of those were filed in the last 90 days.
- Are PTCT insiders net buyers or net sellers?
- Across the full Form 4 history for PTCT, 4 transactions (0%) were open-market purchases and 766 (58%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does PTCT insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is PTCT in?
- PTC THERAPEUTICS, INC. (PTCT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $5.65B.
Methodology & sources
Every PTCT insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.